These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 31456438)

  • 1. Pembrolizumab for the treatment of diffuse large B-cell lymphoma.
    Sheikh S; Kuruvilla J
    Expert Opin Biol Ther; 2019 Nov; 19(11):1119-1126. PubMed ID: 31456438
    [No Abstract]   [Full Text] [Related]  

  • 2. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
    Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
    Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
    Matsuki E; Younes A
    Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.
    Goodman A; Patel SP; Kurzrock R
    Nat Rev Clin Oncol; 2017 Apr; 14(4):203-220. PubMed ID: 27805626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus‒Positive and ‒Negative Relapsed or Refractory Non-Hodgkin Lymphomas.
    Kim SJ; Hyeon J; Cho I; Ko YH; Kim WS
    Cancer Res Treat; 2019 Apr; 51(2):611-622. PubMed ID: 30025443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.
    Xu-Monette ZY; Zhou J; Young KH
    Blood; 2018 Jan; 131(1):68-83. PubMed ID: 29118007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying and treating candidates for checkpoint inhibitor therapies in multiple myeloma and lymphoma.
    Hradska K; Kascak M; Hajek R; Jelinek T
    Expert Rev Hematol; 2020 Apr; 13(4):375-392. PubMed ID: 32116068
    [No Abstract]   [Full Text] [Related]  

  • 8. [Not Available].
    Gilardin L; Amorim S; Bernard S; Ravdan O; Thieblemont C; Brice P
    Bull Cancer; 2018 Dec; 105 Suppl 1():S50-S58. PubMed ID: 30595199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pembrolizumab in the treatment of refractory primary mediastinal large B-cell lymphoma: safety and efficacy.
    Camus V; Bigenwald C; Ribrag V; Lazarovici J; Jardin F; Sarkozy C
    Expert Rev Anticancer Ther; 2021 Sep; 21(9):941-956. PubMed ID: 34233557
    [No Abstract]   [Full Text] [Related]  

  • 10. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Where does PD-1 blockade fit in HL therapy?
    Herrera AF
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):213-220. PubMed ID: 30504313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pembrolizumab for the treatment of cervical cancer.
    Marret G; Borcoman E; Le Tourneau C
    Expert Opin Biol Ther; 2019 Sep; 19(9):871-877. PubMed ID: 31322926
    [No Abstract]   [Full Text] [Related]  

  • 13. Understanding Immune Evasion and Therapeutic Targeting Associated with PD-1/PD-L1 Pathway in Diffuse Large B-cell Lymphoma.
    Song MK; Park BB; Uhm J
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30884772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Immune System Alterations in Hodgkin Lymphoma.
    Grover NS; Savoldo B
    Curr Hematol Malig Rep; 2017 Aug; 12(4):358-369. PubMed ID: 28780614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pembrolizumab for the treatment of Hodgkin Lymphoma.
    Al Hadidi SA; Lee HJ
    Expert Opin Biol Ther; 2020 Nov; 20(11):1275-1282. PubMed ID: 33006479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas.
    Wang Y; Wu L; Tian C; Zhang Y
    Ann Hematol; 2018 Feb; 97(2):229-237. PubMed ID: 29128997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphoma.
    Godfrey J; Mei M; Chen L; Song JY; Bedell V; Budde E; Armenian S; Puverel S; Nikolaenko L; Chen R; Daniels S; Kennedy N; Peters L; Rosen ST; Forman SJ; Popplewell LL; Kwak LW; Herrera AF
    Haematologica; 2024 Feb; 109(2):533-542. PubMed ID: 37470137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Dysfunction in Non-Hodgkin Lymphoma: Avenues for New Immunotherapy-Based Strategies.
    Falchi L
    Curr Hematol Malig Rep; 2017 Oct; 12(5):484-494. PubMed ID: 28822058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-1/PD-L1 blockade in renal cell cancer.
    Beckermann KE; Johnson DB; Sosman JA
    Expert Rev Clin Immunol; 2017 Jan; 13(1):77-84. PubMed ID: 27426025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now.
    Bellmunt J; Powles T; Vogelzang NJ
    Cancer Treat Rev; 2017 Mar; 54():58-67. PubMed ID: 28214651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.